RECONCILE CHEWABLE TABLET FOR DOGS 8 MG

देश: ऑस्ट्रेलिया

भाषा: अंग्रेज़ी

स्रोत: APVMA (Australian Pesticides and Veterinary Medicines Authority)

सक्रिय संघटक:

FLUOXETINE HYDROCHLORIDE

थमां उपलब्ध:

REDCAP SOLUTIONS PTY LTD

INN (इंटरनेशनल नाम):

fluoxetine as HCl(8mg/Tb)

फार्मास्यूटिकल फॉर्म:

ORAL TABLET

रचना:

FLUOXETINE HYDROCHLORIDE UNGROUPED Active 8.0 mg

पैकेज में यूनिट:

30 Tablets

वर्ग:

VM - Veterinary Medicine

द्वारा बनाया गया:

NEXCYON PHARMACEUTIC

चिकित्सीय समूह:

DOG | BITCH | CASTRATE | PUPPY

चिकित्सीय क्षेत्र:

CENTRAL NERVOUS SYSTEM

चिकित्सीय संकेत:

ANXIETY DISORDER

उत्पाद समीक्षा:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [ANXIETY DISORDER]; Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [ANXIETY DISORDER]; For use as an aid in the treatment of canine separation anxiety and reduction of associated behaviours in conjunction with a behaviour modification plan in dogs.Do not use in dogs with a history of epilepsy or history of seizures. See label for other details and precautions.

प्राधिकरण का दर्जा:

Registered

प्राधिकरण की तारीख:

2023-07-01

सूचना पत्रक

®®
®
SH8720DEALX
(V01-10-2009) CA4203
SH8720DEALX
Chewable Tablets for Dogs
Chewable Tablets for Dogs
ACTIVE CONSTITUENT:
Each tablet contains 8 mg fluoxetine (as fluoxetine hydrochloride).
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
FOR USE AS AN AID IN THE
TREATMENT OF CANINE SEPARATION
ANXIETY AND REDUCTION OF
ASSOCIATED BEHAVIOURS IN
CONJUNCTION WITH A BEHAVIOUR
MODIFICATION PLAN IN DOGS
WEIGHING 4 TO 8 KG.
30 TABLETS
8
mg
8
mg
READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT
DIRECTIONS FOR USE
THESE TABLETS MUST BE DISPENSED IN A CHILD-RESISTANT CONTAINER.
CONTRAINDICATIONS
RECONCILE CHEWABLE TABLETS ARE CONTRAINDICATED IN DOGS WITH
EPILEPSY OR A HISTORY OF SEIZURES. RECONCILE TABLETS SHOULD NOT
BE GIVEN CONCOMITANTLY WITH DRUGS THAT LOWER THE SEIZURE
THRESHOLD (EG. PHENOTHIAZINES SUCH AS ACEPROMAZINE OR
CHLORPROMAZINE).
RECONCILE CHEWABLE TABLETS ARE CONTRAINDICATED IN DOGS WITH A
KNOWN HYPERSENSITIVITY TO FLUOXETINE HYDROCHLORIDE OR OTHER
SSRI’S (SELECTIVE SEROTONIN REUPTAKE INHIBITORS).
RECONCILE CHEWABLE TABLETS SHOULD NOT BE GIVEN IN
COMBINATION WITH MONOAMINE OXIDASE INHIBITOR (MAOI)
[E.G. SELEGILINE HYDROCHLORIDE (L-DEPRENYL) OR AMITRAZ], OR WITHIN
A MINIMUM OF 14 DAYS OF DISCONTINUING THERAPY WITH AN MAOI.
BECAUSE FLUOXETINE AND ITS MAJOR METABOLITES, NORFLUOXETINE,
HAVE LONG HALF-LIVES, A 6-WEEK WASHOUT INTERVAL SHOULD BE
OBSERVED FOLLOWING DISCONTINUATION OF THERAPY WITH RECONCILE
CHEWABLE TABLETS PRIOR TO THE ADMINISTRATION OF ANY DRUG THAT
MAY ADVERSELY REACT WITH FLUOXETINE OR NORFLUOXETINE.
PRECAUTIONS:
RECONCILE Chewable tablets have not been evaluated for the treatment
of other behavioural disorders. RECONCILE Chewable tablets are not
recommended for the treatment of aggression.
The safety of RECONCILE Chewable Tablets in dogs less than 6 months of
age or in dogs weighing less than 4kg has not been evaluated as no
studies have been conducted.
The safety of RECONCILE Chewable Tablets in breeding, pregnant or
lactating dogs has not been evaluated a